Nothing Special   »   [go: up one dir, main page]

EP2208798B1 - Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques - Google Patents

Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques Download PDF

Info

Publication number
EP2208798B1
EP2208798B1 EP10161572.2A EP10161572A EP2208798B1 EP 2208798 B1 EP2208798 B1 EP 2208798B1 EP 10161572 A EP10161572 A EP 10161572A EP 2208798 B1 EP2208798 B1 EP 2208798B1
Authority
EP
European Patent Office
Prior art keywords
mir
hsa
mmu
seq
ambi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10161572.2A
Other languages
German (de)
English (en)
Other versions
EP2208798A1 (fr
Inventor
Thomas Thum
Johann Bauersachs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Priority to EP10161572.2A priority Critical patent/EP2208798B1/fr
Publication of EP2208798A1 publication Critical patent/EP2208798A1/fr
Application granted granted Critical
Publication of EP2208798B1 publication Critical patent/EP2208798B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the invention relates to microRNAs (miRNAs) for the diagnosis, prophylaxis and / or therapy of heart diseases.
  • the invention particularly relates to SEQ ID NO: 1 to SEQ ID NO: 29 for the diagnosis, prophylaxis and / or therapy of heart disease.
  • the invention relates to the use of these sequences for the preparation of a medicament for heart diseases and for their diagnosis.
  • a method for diagnosing a heart disease, a kit and an expression vector with these sequences, a cell containing the expression vector, a method of modulating a heart disease and a method of screening a pharmaceutically active compound for the treatment and / or prophylaxis of heart disease of the invention are provided.
  • MicroRNAs are small noncoding RNA molecules that can post-translationally regulate gene expression by degrading the messenger RNA.
  • the total number of different miRNAs is estimated at about 300-500. This makes miRNAs about 1% of the human genome. miRNAs have been discovered in several species and appear to be highly conserved.
  • miRNA is estimated to regulate up to 30% of the genes of the human genome.
  • miRNA genes are transcribed by RNA polymerase II into long primary miRNAs (pri-miRNA). Further processing of these pri-miRNAs occurs stepwise and in different compartments.
  • Pri-miRNAs are first converted in the cell nucleus by the RNase III enzyme Drosha into precursor miRNAs (precursor miRNAs) comprising about 70-80 nucleotides. Drosha forms with the RNA-binding protein DGCR8 to a microprocessor complex.
  • Pre-miRNA hairpins are transported out of the cell nucleus by the protein exportin-5 and Ran-GTP as cofactor.
  • the pre-miRNA is processed by the RNase II enzyme Dicer into approximately 22 nucleotide duplex miRNAs.
  • Dicer interacts with the double-band RNA-binding protein TRBP.
  • the miRNA duplex molecules are then unraveled to produce mature miRNA.
  • This mature miRNA is then incorporated into a ribonucleoprotein complex (miRNP), which is very similar to the RNA-induced silcencing complex (RISC), the effector molecule of interfering RNA (RNAi) (Hutvagner and Zamore, 2002).
  • miRNP ribonucleoprotein complex
  • RISC RNA-induced silcencing complex
  • RNAi interfering RNA
  • miRNAs can lead to a downregulation of the respective target gene via two different mechanisms: a) Translational inhibition or b) Target mRNA cleavage.
  • the choice of mechanism depends on the degree of complementarity between miRNA and the target gene in combination with a so-called Argonaute protein (Meister et al., 2005). Nearly perfect complementarity leads to a cleavage of the target gene with subsequent RNA degradation; while translational inhibition occurs with only partial complementarity (Hutvagner and Zamore, 2002). The exact mechanism of translational inhibition is not yet known (cf. Fig. 1 which represents the state of the art).
  • miRNAs While some mechanisms for the regulation of differentiation processes by miRNAs have already been elucidated (Harfe, 2005; Hornstein et al., 2005), the regulation of physiological functions by miRNAs is largely unknown. The large number of miRNAs and their regulated target genes predicts an important role for miRNA in the development and progression of various diseases. For example, the majority of miRNAs identified in different tumor samples are down-regulated (Lu et al., 2005).
  • miRNA Another possible role of miRNA in the control of remodeling processes after myocardial infarction or other heart diseases, such as Hypertrophy or myocarditis seems likely, but information about it is not yet available.
  • cardiac remodeling (Pfeffer and Braunwald, 1990) describes the remodeling processes of the heart under pathophysiological conditions after a myocardial infarction or in other diseases (e.g., myocarditis) that can lead to heart failure. While in the early phase after myocardial infarction necrosis of the ischemic myocardium with consequent scarring occurs in the long-term course in not directly affected by the infarction myocardium, which are initially regarded as healing and adaptation processes.
  • the thinning and dilatation of the infarcted myocardial wall can lead to infarct expansion early (days to weeks) in the postinfarction phase; late remodeling (months to years) is caused by a structural remodeling of the surviving myocardium characterized by myocyte hypertrophy, interstitial fibrosis, apoptotic cardiomyocyte loss, and dilation and deformation of the ventricle.
  • cardiac remodeling involves molecular, cellular and interstitial changes. Not only cardiomyocytes are affected (phenotype change with hypertrophy and reduced contractility, necrosis, apoptosis), but also in particular the extracellular matrix and a change of the inflammatory environment. Cardiac remodeling is influenced by hemodynamic changes, neurohormonal activation, inflammatory cytokines, and a variety of other processes. Chronic heart failure, as well as acute myocardial infarction, are characterized by increased plasma levels of proinflammatory cytokines (including tumor necrosis factor alpha, interleukin-1-beta, -2 and -6) and their soluble receptors. In the insufficient myocardium inflammatory cytokines are expressed.
  • proinflammatory cytokines including tumor necrosis factor alpha, interleukin-1-beta, -2 and -6
  • the present invention is therefore based on the object of specifying various miRNA sequences which are suitable for the diagnosis, prophylaxis and / or therapy of heart diseases.
  • the invention relates to an inhibitor of a miRNA of SEQ ID NO: 14, for use in a method for the prophylaxis and / or therapy of heart disease.
  • the invention relates to the use of an inhibitor of a miRNA of SEQ ID NO: 14 for the manufacture of a medicament for the prophylaxis and / or therapy of heart disease.
  • the invention relates to a method for in vitro diagnosis of heart disease; and a method for screening a pharmaceutically active compound for the treatment and / or prophylaxis of heart disease.
  • the present invention relates an inhibitor of a miRNA of SEQ ID NO: 14, for use in a method for the prophylaxis and / or therapy of heart disease, wherein the inhibitor is a chemically modified oligonucleotide, and wherein the oligonucleotide is synthesized as oligonucleotide reverse complementary to SEQ ID NO: 14 ,
  • the invention relates to the use of an inhibitor of a miRNA of SEQ ID NO: 14 for the manufacture of a medicament for the prophylaxis and / or therapy of heart disease.
  • the heart disease is a myocardial infarction, heart failure, in particular chronic heart failure and / or cardiac hypertrophy.
  • the miRNA isolation could be optimized by adding a further separation step by gel electrophoresis to the extent that a good label for the subsequent hybridization and detection (detection) of miRNAs on specially spotted special miRNA microarrays (in cooperation with the IZKF Microarray Facility, Dr. S. Kneitz) was possible (see Fig. 2 and Fig. 3 ).
  • a good label for the subsequent hybridization and detection (detection) of miRNAs on specially spotted special miRNA microarrays in cooperation with the IZKF Microarray Facility, Dr. S. Kneitz
  • Fig. 2 and Fig. 3 By comparison From healthy with chronic infarcted myocardium of the rat numerous deregulated miRNAs could be identified, which represent interesting target structures for subsequent research approaches or interesting diagnostic markers.
  • miRNA206 (SEQ ID NO: 8) Cytochrome b5 Superoxide dismutase [Cu-Zn] Cyclin H Angiopoietin-like 2 miRNA211 (SEQ ID NO: 9) Bone morphogenetic protein 10 precursor (BMP-10) Intermediate conductivity (calcium-activated) Potassium Channel Protein 4 (SK4) (KCa4) Nitric oxide synthase, brain m (EC 1.14.13.39) (NOS type I) (neuronal NOS) (N-NOS) Potassium Channel Voltage-Mediated Subfamily H Member 7 (Voltage-gated potassium channel subunit Kv11.3) nestin Matrix metalloproteinase-9 precursor (EC 3.4.24.35) (MMP-9) Atrial Natriuretic Peptide Receptor B Precursor (ANP-B) Myogenic factor 6 Vascular Cell Adhesion Protein 1 Precursor (V-CAM 1) (CD106 Antigen) miRNA212 (SEQ ID NO: 10) Myosin 5B (myosin
  • Single highly regulated miRNAs can be detected by downregulation (by liposomal transfection of the specific miRNA) or downregulation (by liposomal transfection of specific miRNA inhibitors ( anti-miRs® , Ambion, UK or Antagomirs, Alnylam, Kulmbach, Germany) of the corresponding miRNA by application Alternatively, other types of transfection can also be used (eg, viral or by nucleofection, or electroporation).
  • the large number of target genes of individual miRNAs normalizes gene expression in its expression after myocardial infarction and restores improved cardiac function.
  • RNA including small RNAs was isolated ( me Vana TM miRNA isolation kit; Ambion, USA). The total RNA was isolated separately and the purified miRNAs were prepared using the FlashPAGE fractionation system (Ambion, USA). Capillary electrophoresis (Bioanalyzer 2100, Agilent, Germany) was used to evaluate the quality of total RNA and the purity of miRNA.
  • MicroRNA obtained from 10 ⁇ g total RNA was labeled with the dye Cy3 (Molecular Probes, USA) using the mir Vana TM miRNA labeling kit (Ambion, USA) according to the manufacturer's instructions. Each target was hybridized in a separate array.
  • Microarrays with up to 384 miRNAs were in our laboratory slides each spotted four times on SCHOTT Nexterion ® Slide E microarray.
  • the oligonucleotide probes were 42-46 nt in length and consisted of an 18-24 nt segment targeting a particular known miRNA derived from human, mouse or rat.
  • the miRNA array data analyzes were performed using the R package from the Bioconductor project ( www.bioconductor.org ). The resulting signal intensities were normalized by variance stabilization (Huber et al., 2002). The quality of all data sets was tested and statistical analysis was performed to evaluate differentially expressed genes using the Limma (Linear Models for Microarray Analysis) package.
  • the core of the Limma package is an implementation of the empirical Bayes linear modeling approach of Smyth and can itself be used for the stability analysis of even smaller sample sizes (Smyth, 2004).
  • the miRNA database miRBase ( http://microrna.sanger.ac.uk/ ) was used to identify potential miRNA targets.
  • the miRanda algorithm was used to screen all available miRNA sequences of a given genome against the 3 'UTR sequences of that genome.
  • the algorithm uses dynamic programming to search for the maximum local complementarity that corresponds to the double-stranded anti-parallel duplex. A positive score is given for complementary base pairing, and a negative score is given for mismatches, openings, and gap-opening and gap-extension extensions.
  • the values derived from the 5 'end of the miRNA were multiplied by a factor to express the importance of perfect Watson-Crick base pairing, which was experimentally observed. Subsequently, a Karlin Altschul normalization was performed (miRBase Targets version 3.0, http://microrna.sanger.ac.uk/targets/v3/).
  • Cardiomyocytes were isolated and cultured by neonatal rats as described (Burkard et al., 2005). More than 95% of the cultured cells showed expression for the cardiomyocyte-specific actinin, which indicates a very high purity of the cell culture.
  • Fluorescent dye (Cy3) -labeled scrambled-miR, -miR-21, -miR-129, and -miR-212 molecules (Cy3-pre-miR miRNAs, Ambion, U.S.A., 100 nM, 48 h) were prepared separately or in vitro Combination by means of a liposomal transfection method (Lipofectamine, Invitrogen, Germany) transfected into cultured cardiomyocytes (Thum et al., 2007; Fig.
  • the surface of the cultured neonatal (48 h after transfection) and adult (72 h after transfection) cardiomyocytes were determined with the image analysis program AxioVison Rel. 4.4 (Carl Zeiss GmbH, Germany). Statistical analyzes were performed by one-way ANOVA followed by several comparisons with the "Fisher's protected least-significant difference" test. The statistical analysis was done with the program Stat-View 5.0 (Abacus Concepts, Berkley, CA, USA). The statistical significance was assumed to be P ⁇ 0.05.
  • the genes ANP, BNP, beta-MHC, alpha skeletal actin, villin2, cspg2, phida1, hsp90, RASA1, MEF2a, cradd and dtna were modulated by miRNA overexpression in their expression so that the level of expression was on the diseased heart ( Fig. 5D . 6E ).
  • Transfection of adult cardiomyocytes with this set of miRNAs also resulted in the development of cellular hypertrophy and activation of fetal gene programs ( Fig. 6D , E, F).
  • Transfection of scrambled miRNAs did not lead to cellular hypertrophy or activation of fetal, pathological gene programs ( Fig. 5 . 6 ).
  • the data identify certain miRNAs as important regulators for the re-activation of fetal gene programs in the deficient human heart and thus provide an important contribution to the explanation of transcriptional changes in heart failure.
  • Table 2 summarizes the SEQ ID NRs, database names (Sanger), and MI designations.
  • Table 2 SEQ ID NO. Name (Sanger) MI designation SEQ ID NO: 1 miR-15b MI 0000438 SEQ ID NO: 2 miR-23a MI 0000079 SEQ ID NO: 3 miR-126 * MI 0000471 SEQ ID NO: 4 miR-128a MI 0000155 SEQ ID NO: 5 miR-134 MI 0000474 SEQ ID NO: 6 miR-149 MI 0000478 SEQ ID NO: 7 miR-151 MI 0000809 SEQ ID NO: 8 miR-206 MI 0000490 SEQ ID NO: 9 miR-211 MI 0000287 SEQ ID NO: 10 miR-212 MI 0000288 SEQ ID NO: 11 miR-214 MI 0000290 SEQ ID NO: 12 miR-328 MI 0000804 SEQ ID NO: 13 miR-371 MI 0000779 SEQ ID NO: 14 miR-21 (hsr miR-21) MI 0000077 SEQ ID NO: 15 mi
  • the inventors After hypertrophy induction on the mouse model, the inventors found increased expression of miR-21 (see above). Therefore, they investigated whether inhibition of miR-21 in vivo leads to prevention of the development of cardiac hypertrophy due to compression (reduction of the aortic diameter by aortic banding operation). They first used bioinformatic analysis and used the database miRBase ( http://microrna.sanger.ac.uk/ ) to look for potential targets with binding sites for the miR-21 in their 3 'untranslated To search areas.
  • sprouty-1 accession number: NM_001097524
  • sarcalumenin accession number: NM_001098814
  • tropomyosin accession number: subsequently, NM 001018005
  • the 3 'untranslated region of SPRY1 mRNA contains several conserved miR binding sites, one of which is a binding site for miR-21 up-regulated in cardiac hypertrophy and cardiac insufficiency.
  • the inventors then injected chemically modified oligonucleotides via a catheter inserted into the jugular vein for specific downregulation of endogenous miR-21 expression (Antagomir®-21, Alnylam).
  • the Antagomir® sequences were synthesized as reverse-complementary oligonucleotides as described in the literature, with Antagomir®-181a additionally being color-marked with Cy3 (Krutzfeldt et al., 2005).
  • Treatment was started 24 hours after the surgical reduction of the aortic banding. In each case, 80 mg / kg / d were then administered intravenously once a day for 3 days once a day. After injection of a Cy-3 labeled Antagomir®, the heart was removed after 3 h and the cardiac uptake of the C3-labeled Antagomir® was analyzed by immunofluorescence. It could be one strong uptake of Antagomir® into the heart ( Fig. 7E ). Surprisingly, real-time (PCR) analyzes showed a strong repression of cardiac miR-21 expression after 3 weeks after initially receiving 3-day treatment with Antagomir®-21 ( Fig. 7F ).
  • Antagomir® 21 treatment in sham-operated mice did not result in a change in heart weight or myocyte size ( FIG. 7G . 8A ).
  • Cardiac function was analyzed by echocardiography and catheter-based volume / pressure measurements. Both left ventricular end-systolic and end-diastolic diameters increased 3 weeks after aortic banding, whereas fractional shingling (a measure of cardiac function) was significantly reduced (Fig. Fig. 8B ).
  • LVEDp left ventricular end-diastolic pressure
  • p 0.09
  • a reduced cardiac ejection fraction 55.9% ⁇ 8.0% (sham) versus 24.7% ⁇ 5.6% (aortic banding), p ⁇ 0.05
  • Antagomir® 21 treatment after aortic banding prevented left ventricular dilatation and normalized fractional shortening (Fig. Fig. 8B ).
  • the ejection fraction was improved and the left ventricular end-diastolic pressure was normalized (EF: 50.1% ⁇ 13.1%, LVEDp: 2.4 ⁇ 1.5 mmHg) after treatment with Antagomir®-21.
  • Modulation of miRNAs in the cardiovascular system could also be successfully used in humans to prevent or as a therapy for cardiovascular diseases such as cardiac hypertrophy, heart failure or myocardial infarction.
  • Substances which increase or prevent miRNA expression in the cardiovascular system may be administered by various routes such as intravenous, intraarterial, intracardiac via catheters or during open heart surgery, subcutaneously, transdermally, inhalatively, orally, rectally, etc. Therapy could be performed in patients with cardiac hypertrophy, after myocardial infarction or in patients with acute or chronic heart failure or coronary heart disease.
  • the prevention of the expression of miR-21, miR-129 and miR-212 seems promising as a causal therapeutic approach for the prevention of various cardiovascular diseases.
  • a myocardial biopsy can be taken. From this, the miRNA can be isolated and the expression level determined.
  • An increase in individual miRNAs or their combination, in particular miR-21 (SEQ ID NO: 14), miR-129, miR-212 (SEQ ID NO: 10), miR-214 (SEQ ID NO: 11), miR-134 ( SEQ ID NO: 5) may be used to diagnose an increased risk of development or even the presence of cardiac hypertrophy and / or cardiac insufficiency.
  • Downregulation of miR-182 (SEQ ID NO: 20) or miR-290 (SEQ ID NO: 24) or a combination thereof may be used to diagnose an increased risk of development or even the presence of cardiac hypertrophy and / or heart failure.
  • miR-21 SEQ ID NO: 14
  • miR-129 miR-212

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

  1. Inhibiteur de miARN ayant la séquence SEQ ID NO:14, pour utilisation dans un procédé pour la prophylaxie et/ou le traitement de maladies cardiaques, l'inhibiteur étant un oligonucléotide chimiquement modifié, et l'oligonucléotide étant synthétisé sous forme d'un oligonucléotide complémentaire inverse de SEQ ID NO:14.
  2. Inhibiteur pour utilisation dans un procédé pour la prophylaxie et/ou le traitement de maladies cardiaques selon la revendication 1, la maladie cardiaque étant un infarctus du myocarde, une insuffisance cardiaque, une insuffisance cardiaque chronique et/ou une hypertrophie cardiaque.
  3. Utilisation d'un inhibiteur d'un miARN ayant la séquence SEQ ID NO:14 pour la fabrication d'un médicament destiné à la prophylaxie et/ou au traitement de maladies cardiaques, pour laquelle l'inhibiteur est un oligonucléotide chimiquement modifié, et l'oligonucléotide est synthétisé sous forme d'un oligonucléotide complémentaire inverse.
  4. Utilisation selon la revendication 3, pour laquelle la maladie cardiaque est un infarctus du myocarde, une insuffisance cardiaque, une insuffisance cardiaque chronique et/ou une hypertrophie cardiaque.
  5. Procédé de diagnostic in vitro d'une maladie cardiaque, le procédé comprenant les étapes :
    (a) mise à disposition d'un échantillon qui a été obtenu d'un individu suspecté de présenter une maladie cardiaque ;
    (b) mesure de la quantité d'expression de la séquence SEQ ID NO:14 dans l'échantillon ;
    une quantité d'expression accrue de SEQ ID NO:14 par rapport à un échantillon témoin étant le signe d'une maladie cardiaque ou une prédisposition à une maladie cardiaque.
  6. Procédé de criblage d'un composé pharmaceutiquement actif pour le traitement et/ou la prophylaxie d'une maladie cardiaque, le procédé comprenant les étapes :
    (a) mise à disposition d'une cellule comprenant au moins un vecteur d'expression comprenant la séquence SEQ ID NO:14,
    (b) mise en contact, avec la cellule, d'un candidat d'un composé pharmaceutiquement actif,
    (c) détermination de l'effet du candidat sur l'expression de la séquence SEQ ID NO:14,
    une modification de l'expression de la séquence SEQ ID NO:14 étant le signe d'un composé pharmaceutiquement actif.
  7. Procédé selon la revendication 5 ou 6, dans lequel la maladie cardiaque est un infarctus du myocarde, une insuffisance cardiaque, une insuffisance cardiaque chronique et/ou une hypertrophie cardiaque.
EP10161572.2A 2006-10-09 2007-10-09 Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques Active EP2208798B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10161572.2A EP2208798B1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090187 2006-10-09
EP10161572.2A EP2208798B1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques
EP07818845A EP2094869B1 (fr) 2006-10-09 2007-10-09 Micro-arn (miarn) pour diagnostiquer et traiter des affections cardiaques

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP07818845.5 Division 2007-10-09

Publications (2)

Publication Number Publication Date
EP2208798A1 EP2208798A1 (fr) 2010-07-21
EP2208798B1 true EP2208798B1 (fr) 2013-08-07

Family

ID=38959649

Family Applications (4)

Application Number Title Priority Date Filing Date
EP10161572.2A Active EP2208798B1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques
EP12157897.5A Active EP2476762B1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour le diagnostic et le traitement de maladies cardiaques
EP12159119A Withdrawn EP2489742A1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques
EP07818845A Active EP2094869B1 (fr) 2006-10-09 2007-10-09 Micro-arn (miarn) pour diagnostiquer et traiter des affections cardiaques

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP12157897.5A Active EP2476762B1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour le diagnostic et le traitement de maladies cardiaques
EP12159119A Withdrawn EP2489742A1 (fr) 2006-10-09 2007-10-09 Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques
EP07818845A Active EP2094869B1 (fr) 2006-10-09 2007-10-09 Micro-arn (miarn) pour diagnostiquer et traiter des affections cardiaques

Country Status (5)

Country Link
US (1) US8906870B2 (fr)
EP (4) EP2208798B1 (fr)
JP (1) JP2010505427A (fr)
AU (1) AU2007306594A1 (fr)
WO (1) WO2008043521A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
CA2603881A1 (fr) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Microarn regulant des cellules musculaires
JP2009536739A (ja) * 2006-05-09 2009-10-15 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント プロテアーゼおよびプロテアーゼ阻害剤の血漿プロファイリングによる拡張期心不全の検出
JP2009544013A (ja) * 2006-07-11 2009-12-10 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント プロテアーゼおよびプロテアーゼ阻害因子のプロファイリングによる心筋梗塞後の心不全の予測
MX2009001281A (es) 2006-08-01 2009-04-16 Univ Texas Identificacion de un micro-arn que activa la expresion de la cadena pesada de beta-miosina.
US8506499B2 (en) * 2007-01-04 2013-08-13 Musc Foundation For Research Development Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling
WO2008147974A1 (fr) 2007-05-23 2008-12-04 University Of South Florida Micro-arn modulant l'immunité et l'inflammation
BRPI0813527A2 (pt) * 2007-07-18 2014-12-30 Univ Colorado Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
BRPI0814991A2 (pt) 2007-07-31 2015-03-31 Univ Texas Micro-rnas que controlam a expressão de miosina e identidade de miofibra.
CA2694930C (fr) * 2007-07-31 2019-11-12 Board Of Regents, The University Of Texas System Famille de micro-arn modulant une fibrose et procedes d'utilisation associes
JP5654352B2 (ja) 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
EP2215228A4 (fr) * 2007-11-23 2012-01-11 Panagene Inc Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer
EP2096171A1 (fr) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg Cibles microARN (miARN) et en aval à des fins de diagnostic et thérapeutiques
WO2009117418A2 (fr) 2008-03-17 2009-09-24 The Board Of Regents Of The University Of Texas System Identification des micro-arn dans l’entretien et la régénération de synapses neuromusculaires
EP2271931A4 (fr) * 2008-04-25 2011-10-12 Merck Sharp & Dohme Biomarqueurs des lésions tissulaires à base de microarn
CA2728069C (fr) 2008-06-16 2018-01-02 Biomedbooster B.V. Moyens et procedes pour combattre, retarder et/ou prevenir une maladie cardiaque
EP2191834A1 (fr) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions et procédé pour traiter des infections à rétrovirus
EP2393945A4 (fr) 2009-02-04 2013-08-07 Univ Texas Ciblage double de mir-208 et mir-499 dans le traitement de troubles cardiaques
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease
EP2228444A1 (fr) * 2009-03-09 2010-09-15 Julius-Maximilians-Universität Würzburg MicroARN à des fins de diagnostic et thérapeutiques dans le cas des maladies cardiovasculaires
EP2907879A3 (fr) * 2009-04-29 2015-10-14 Academisch Medisch Centrum bij de Universiteit van Amsterdam Moyens et procédés pour combattre, prévenir et/ou déterminer une insuffisance cardiaque, ou un risque d'insuffisance cardiaque
WO2010130351A1 (fr) * 2009-05-15 2010-11-18 Bayer Schering Pharma Ag Micro-arn comme biomarqueurs et cibles thérapeutiques pour l'insuffisance cardiaque
MX2011012418A (es) 2009-05-20 2012-07-20 Univ Texas Identificacion de micro-arns implicados en la remodelacion posterior al infarto de miocardio y en la insuficiencia cardiaca.
PL2604691T3 (pl) * 2009-08-06 2015-05-29 Univ Maastricht Środki i sposoby przeciwdziałania, opóźniania i/lub zapobiegania włączaniu niekorzystnego metabolizmu energetycznego w chorobach serca
US8592151B2 (en) * 2009-11-17 2013-11-26 Musc Foundation For Research Development Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
AU2010328019A1 (en) * 2009-12-09 2012-06-28 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
US20110229972A1 (en) * 2010-03-19 2011-09-22 The Penn State Research Foundation Compositions and methods for material transfer into cells
WO2011127219A1 (fr) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Biomarqueurs circulants pour une maladie
SG184821A1 (en) * 2010-04-21 2012-11-29 Amc Amsterdam Means and methods for determining risk of cardiovascular disease
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2011154553A2 (fr) 2010-06-11 2011-12-15 Cellartis Ab Nouveaux microarn pour la détection et l'isolement de types cellulaires cardiaques dérivés de cellules souches embryonnaires humaines
WO2012012716A2 (fr) * 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Ciblage de microarn pour le traitement de la fibrose
ES2374244B1 (es) * 2010-08-02 2012-12-26 Universidad De Jaén MicroRNA útil para el tratamiento de canalopatías arritmogénicas.
CA2817371A1 (fr) 2010-12-15 2012-06-21 Miragen Therapeutics Inhibiteurs de microarn comprenant des nucleotides bloques
EP2663323B1 (fr) * 2011-01-14 2017-08-16 The General Hospital Corporation Procédés de ciblage du mir-128 en vue de la régulation du métabolisme du cholestérol/des lipides
UA115652C2 (uk) 2011-04-25 2017-12-11 Реґюлус Терап'Ютікс Інк. Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
EP2753696B1 (fr) * 2011-09-06 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Famille des miarn-212/132 comme cible thérapeutique
EP2763703B1 (fr) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Régulation de l'homéostasie énergétique du corps entier par la régulation de microarn
EP2584040A1 (fr) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Composés pour le traitement de lésions ischémiques
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US8969317B2 (en) 2012-04-25 2015-03-03 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
JP2015521054A (ja) 2012-06-05 2015-07-27 カプリコール，インコーポレイテッド 心臓組織から心臓幹細胞を作製するための最適化方法および心臓治療におけるそれらの使用
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US20160060697A1 (en) 2012-11-27 2016-03-03 Luxembourg Institute Of Health Compositions and Methods for Evaluating Heart Failure
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
KR101757806B1 (ko) * 2014-06-11 2017-07-27 가톨릭관동대학교산학협력단 microRNA-182 및 Bnip3의 발현 수준을 이용한 허혈성 심장 질환의 진단정보 제공방법
CA2962444C (fr) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cellules derivees de la cardiosphere et exosomes secretes par ces cellules dans le traitement d'une dystrophie musculaire
EP3247716A4 (fr) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Inhibiteurs de mir-92 et utilisations associées
AU2016221451B2 (en) * 2015-02-17 2021-10-14 Société des Produits Nestlé S.A. Methods for diagnosing chronic valvular disease
WO2016133395A1 (fr) 2015-02-20 2016-08-25 Rijksuniversiteit Groningen Miarn circulants chez des patients atteints d'une insuffisance cardiaque aiguë
US9885018B1 (en) * 2015-03-16 2018-02-06 The Regents Of The University Of Colorado, A Body Corporate High efficiency reprogramming of fibroblasts into cardiomyocytes
JP2018515097A (ja) * 2015-05-08 2018-06-14 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 慢性心不全の診断と予後予測の方法
DE102015216782B3 (de) * 2015-09-02 2017-01-26 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Verwendung von im Blutserum oder Blutplasma zirkulierenden microRNAs zur Identifikation biopsiepflichtiger Patienten und als Marker zur Differentialdiagnose einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens
EP3402543B1 (fr) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cellules dérivées de cardiosphères et exosomes sécrétés par ces cellules dans le traitement d'une insuffisance cardiaque à fraction d'éjection préservée
WO2017210652A1 (fr) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Exosomes dérivés de cdc pour le traitement des tachyarythmies ventriculaires
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
WO2019126068A1 (fr) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Vésicules extracellulaires modifiées pour une administration tissulaire améliorée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060247193A1 (en) * 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
US8969314B2 (en) * 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
EP1648914A4 (fr) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
EP1791954A1 (fr) 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions et methodes de traitement de pathologies dans lesquelles la regulation d'une voie biologique associee a l'acetylcholinesterase (ache) est benefique
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20090306181A1 (en) * 2006-09-29 2009-12-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
CA2671294A1 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Genes et voies genetiques regules par mir-21 utilises en tant que cibles pour une intervention therapeutique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Declaration by Prof. Thomas Thum dated 13-07-2011 (3 pp.). *
HALAPAS A ET AL: "In vivo models for heart failure research.", IN VIVO (ATHENS, GREECE) 2008 NOV-DEC LNKD- PUBMED:19181005, vol. 22, no. 6, November 2008 (2008-11-01), pages 767 - 780, ISSN: 0258-851X *
LITWIN S E ET AL: "Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure.", CIRCULATION 15 MAY 1995 LNKD- PUBMED:7743628, vol. 91, no. 10, 15 May 1995 (1995-05-15), pages 2642 - 2654, ISSN: 0009-7322 *
MIYAMOTO M I ET AL: "Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 18 JAN 2000 LNKD- PUBMED:10639159, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 793 - 798, ISSN: 0027-8424 *
ROCKMAN H A ET AL: "Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 15 SEP 1991 LNKD- PUBMED:1832775, vol. 88, no. 18, 15 September 1991 (1991-09-15), pages 8277 - 8281, ISSN: 0027-8424 *
THOMAS THUM ET AL: "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 456, no. 7224, 1 December 2008 (2008-12-01), pages 980 - 986, XP002624252, ISSN: 0028-0836, [retrieved on 20081130], DOI: 10.1038/NATURE07511 *

Also Published As

Publication number Publication date
WO2008043521A3 (fr) 2008-09-12
AU2007306594A1 (en) 2008-04-17
EP2489742A1 (fr) 2012-08-22
EP2094869B1 (fr) 2012-07-25
EP2208798A1 (fr) 2010-07-21
JP2010505427A (ja) 2010-02-25
US8906870B2 (en) 2014-12-09
EP2094869A2 (fr) 2009-09-02
EP2476762A1 (fr) 2012-07-18
EP2476762B1 (fr) 2014-01-08
WO2008043521A2 (fr) 2008-04-17
US20100010073A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
EP2208798B1 (fr) Micro-ARN (miARN) pour diagnostiquer et traiter des affections cardiaques
Zhang et al. Endothelial dysfunction in diabetes and hypertension: role of microRNAs and long non-coding RNAs
Van Rooij et al. Toward microrna–based therapeutics for heart disease: The sense in antisense
Rawal et al. Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease
Horie et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes
Soares et al. Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions
Satoh et al. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy
Li et al. Noncoding RNAs in cardiac hypertrophy
JP5871791B2 (ja) 心不全または心不全の危険性を中和、予防および／または決定する手段および方法
US20100267804A1 (en) Differential expression of micrornas in nonfailing versus failing human hearts
WO2010103015A1 (fr) Micro-arn destiné à des fins diagnostiques et thérapeutiques dans des maladies cardiovasculaires
Sun et al. Myocardial infarction-induced hippocampal microtubule damage by cardiac originating microRNA-1 in mice
Jiang et al. β-Sitosterol regulated microRNAs in endothelial cells against an oxidized low-density lipoprotein
Yang et al. Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo
EP2714934B1 (fr) Méthodes et compositions de détermination d'insuffisance cardiaque ou de risque d'insuffisance cardiaque
Jiao et al. MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus
WO2010130351A1 (fr) Micro-arn comme biomarqueurs et cibles thérapeutiques pour l'insuffisance cardiaque
Cheung et al. Sex-different and growth hormone-regulated expression of microRNA in rat liver
Kong et al. Inhibition of long noncoding RNA Gm41724 alleviates pressure overload-induced cardiac fibrosis by regulating lamina-associated polypeptide 2α
US20120040906A1 (en) Protein targets in disease
KR101736025B1 (ko) 순환형 노화 마커를 이용한 역노화 유도 방법
Alissa et al. From Molecules to Heart Regeneration: Understanding the Complex and Profound Role of Non-Coding RNAs in Stimulating Cardiomyocyte Proliferation for Cardiac Repair
Oltra Epigenetics of muscle disorders
Clauss et al. microRNA-mediated cardiac remodeling in athletes
He et al. Serum-derived exosomal circENC1 inhibits SMC phenotypic switching to stabilize atherosclerotic plaques by interacting with miR-513a-5p and inhibiting MYH9 degradation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2094869

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BAUERSACHS, JOHANN

Inventor name: THUM, THOMAS

17P Request for examination filed

Effective date: 20110517

17Q First examination report despatched

Effective date: 20110803

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDIZINISCHE HOCHSCHULE HANNOVER

AC Divisional application: reference to earlier application

Ref document number: 2094869

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 625798

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502007012140

Country of ref document: DE

Effective date: 20131002

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130807

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131209

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130904

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131207

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131108

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

BERE Be: lapsed

Owner name: MEDIZINISCHE HOCHSCHULE HANNOVER

Effective date: 20131031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140508

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502007012140

Country of ref document: DE

Effective date: 20140508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131009

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 625798

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20071009

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130807

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220915

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220921

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20220921

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221003

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502007012140

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231009

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240501

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031